Autor segons l'article: Martínez-Sanz J; Blanco JR; Muriel A; Pérez-Elías MJ; Rubio-Martín R; Berenguer J; Peraire J; Bernal E; Martínez OJ; Serrano-Villar S; Moreno S
Departament: Medicina i Cirurgia
Autor/s de la URV: Peraire Forner, José Joaquin
Paraules clau: Weight gain Tenofovir disoproxil fumarate Risk Obesity Hiv Gain Disease Comorbidity Body-weight trajectory Antiretroviral agents Alafenamide
Resum: INTRODUCTION: Weight gain after starting antiretroviral therapy (ART) is a major problem that can increase morbidity. Our main objective was to evaluate the effects of initial ART on weight change in a large prospective cohort of HIV-positive individuals. METHODS: This was a prospective cohort study of 13,198 subjects included in the Spanish HIV Research Network (CoRIS) between January 2004 and November 2018. We included subjects who started triple ART and achieved HIV RNA suppression within 48 weeks. We fitted linear mixed models adjusted for potential confounders to compare longitudinal changes in weight. We used Cox proportional-hazard models to compare treatment groups' times to transition to a higher body mass index (BMI) category. RESULTS: We analysed data from a total of 1631 individuals resulting in 14,965 persons/years and 14,085 observations. Individuals retained in the final multivariable model were representative of the overall cohort. NNRTI-based first-line ART was associated with a lower average weight gain compared to PI- (+0.7 kg per year, 95% CI 0.5 to 1.0, p < 0.001) and INSTI-based (+0.9 kg per year, 95% CI 0.7 to 1.1, p < 0.001) regimens. Individuals starting ART with TAF+FTC had greater weight gain than those receiving TDF+FTC (+0.8 kg per year, 95% CI 0.3 to 1.4, p = 0.004). Women and black persons presented a greater weight gain than men and non-black individuals. Differences in weight trajectories were driven mainly by changes during the first year of ART. The NNRTI group was less likely to transition from normal weight to overweight than the PI (aHR 1.48, 95% CI 1.18 to 1.85) and INSTI groups (aHR 1.30, 95% CI 1.03 to 1.64). PIs but not INSTIs were associated with a higher rate of overweight-to-obesity shift (aHR 2.17, 95% CI 1.27 to 3.72). No differences were found among INSTIs in the transition to a higher BMI category. CONCLUSIONS: INSTI- and PI-based first-line ARTs are associated with greater weight gain compared to NNRTI-based ART. Within the NRTIs, TAF+FTC was most strongly associated with weight gain. This heterogeneous effect of ART on body weight could affect the long-term risk of some non-communicable diseases.
Àrees temàtiques: Saúde coletiva Public health, environmental and occupational health Planejamento urbano e regional / demografia Medicina ii Medicina i Interdisciplinar Infectious diseases Immunology General medicine Enfermagem Economia Direito Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Administração pública e de empresas, ciências contábeis e turismo
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: joaquim.peraire@urv.cat
Identificador de l'autor: 0000-0001-7808-5479
Data d'alta del registre: 2024-07-27
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25732
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Journal Of The International Aids Society. 24 (5): e25732-
Referència de l'ítem segons les normes APA: Martínez-Sanz J; Blanco JR; Muriel A; Pérez-Elías MJ; Rubio-Martín R; Berenguer J; Peraire J; Bernal E; Martínez OJ; Serrano-Villar S; Moreno S (2021). Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study. Journal Of The International Aids Society, 24(5), e25732-. DOI: 10.1002/jia2.25732
DOI de l'article: 10.1002/jia2.25732
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications
Repositori URV